Quick Answer
Ultragenyx Pharmaceutical Inc. reported Total Revenue of $673.00 million for fiscal year 2025.
Ultragenyx Pharmaceutical Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $673.00M | +20.2% |
| 2024 | $560.00M | +29.0% |
| 2023 | $434.00M | +19.5% |
| 2022 | $363.33M | +3.4% |
| 2021 | $351.41M | +29.7% |
| 2020 | $271.03M | +161.3% |
| 2019 | $103.71M | +101.4% |
| 2018 | $51.49M | +1871.5% |
| 2017 | $2.61M | +1863.9% |
| 2016 | $133.0K | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $159.93M | +14.7% | -3.9% |
| June 30, 2025 | $166.50M | +13.2% | +19.5% |
| March 31, 2025 | $139.29M | +28.0% | -0.1% |
| September 30, 2024 | $139.49M | +42.3% | -5.1% |
| June 30, 2024 | $147.03M | +35.7% | +35.1% |
| March 31, 2024 | $108.83M | +8.3% | +11.0% |
| September 30, 2023 | $98.05M | +8.1% | -9.5% |
| June 30, 2023 | $108.31M | +21.2% | +7.8% |
- Ultragenyx Pharmaceutical Inc. showed an increase of +20.2% in Total Revenue compared to the prior fiscal year.
- Over the 2016–2025 period, Ultragenyx Pharmaceutical Inc.’s total revenue has grown by 505915.0% (from $133.0 thousand to $673.00 million).
- The most recent figure is from Ultragenyx Pharmaceutical Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: